Amlodipine/bisoprolol fumarate/perindopril arginine - Servier
Alternative Names: Amlodipine/bisoprolol fumarate/perindopril arginine; bisoprolol fumarate/amlodipine/perindopril arginine - Servier; bisoprolol fumarate/perindopril arginine/amlodipine - Servier; perindopril arginine/amlodipine/bisoprolol fumarate - Servier; perindopril arginine/bisoprolol fumarate/amlodipine - ServierLatest Information Update: 24 Dec 2024
At a glance
- Originator Servier
- Class Alcohols; Amines; Antihypertensives; Azabicyclo compounds; Carboxylic acids; Chlorobenzenes; Dihydropyridines; Esters; Ethers; Heart failure therapies; Indoles; Ischaemic heart disorder therapies; Obesity therapies; Phenyl ethers; Propanolamines; Small molecules
- Mechanism of Action ACE inhibitors; Beta 1 adrenergic receptor antagonists; Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Essential hypertension
Most Recent Events
- 24 Dec 2024 Chemical structure information added.
- 13 Aug 2024 Discontinued - Phase-III for Essential hypertension in Russia (PO), before August 2024
- 18 Dec 2018 Servier completes phase III trial in Essential hypertension in Russia (PO) in December 2021 (NCT05288400)